Neuroendocrine differentiation of prostate cancer

Asian Journal of Andrology

Volumn 15, Issue 3, 2013, Pages 328-332

  Li, Zhen ^a   Chen, Clark J ^a   Wang, Jason K ^a   Hsia, Elaine ^a   Li, Wei ^a   Squires, Jill ^a   Sun, Yin ^a   Huang, Jiaoti ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 8;

CELL DIFFERENTIATION; GENE; HUMAN; NEUROENDOCRINE TUMOR; NONHUMAN; NOTE; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATE HYPERTROPHY; RB GENE; SMALL CELL NEUROENDOCRINE CARCINOMA;

ADENOCARCINOMA; ANIMALS; CARCINOMA, NEUROENDOCRINE; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; GENES, RETINOBLASTOMA; HUMANS; INTERLEUKIN-8; MALE; MICE; MUTATION; NEUROENDOCRINE CELLS; PROSTATIC NEOPLASMS; RECEPTORS, INTERLEUKIN-8B; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84877310195     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1038/aja.2013.7     Document Type: Note

References (30)

1. Sun Y, Niu J, Huang J. Neuroendocrine differentiation in prostate cancer.Am J Transl Res 2009; 1: 148-62.
2. Yuan TC, Veeramani S, Lin MF. Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferen tiation of prostate adenocarcinoma cells. Endocr Relat Cancer 2007; 14: 531-47.
3. Vashchenko N, Abrahamsson PA. Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities. Eur Urol 2005; 47: 147-55.
4. Huang J, Yao JL, di Sant'agnese PA, Yang Q, Bourne PA et al. Immunohistochemical characterization of neuroendocrine cells in prostate cancer. Prostate 2006; 66: 1399-406.
5. Huss WJ, Gregory CW, Smith GJ. Neuroendocrine cell differentiation in the CWR22 human prostate cancer xenograft: association with tumor cell proliferation prior to recurrence. Prostate 2004; 60: 91-7.
6. Deeble PD, Cox ME, Frierson HF Jr, Sikes RA, Palmer JB et al. Androgen-independent growth and tumorigenesis of prostate cancer cells are enhanced by the presence of PKA-differentiated neuroendocrine cells. Cancer Res 2007; 67: 3663-72.
7. Uchida K, Masumori N, Takahashi A, Itoh N, Kato K et al. Murine androgen-independent neuroendocrine carcinoma promotes metastasis of human prostate cancer cell line LNCa P. Prostate 2006; 66: 536-45.
8. Tawadros T, Alonso F, Jichlinski P, Clarke NW, Calandra T et al. Release of macrophage migration inhibitory factor by neuroendocrine differentiated LNCa P cells sustains the proliferation and survival of prostate cancer cells. Endocr Relat Cancer; e-pub ahead of print 3 December 2012; doi: 10.1530/ERC-12-0286.
9. Dasilva JO, Amorino GP, Casarez EV, Pemberton B, Parsons SJ. Neuroendocrine-derived peptides promote prostate cancer cell survival through activation of IGF-1R signaling. Prostate; e-pub ahead of print 28 November 2012; doi: 10.1002/pros.22624.
10. Burchardt T, Burchardt M, Chen MW, Cao Y, de la Taille A et al. Transdifferentiation of prostate cancer cells to a neuroendocrine cell phenotype in vitro and in vivo. J Urol 1999; 162: 1800-5.
11. Lee LF, Louie MC, Desai SJ, Yang J, Chen HW et al. Interleukin-8 confers androgen-independent growth and migration of LNCa P: differential effects of tyrosine kinases Src and FAK. Oncogene 2004; 23: 2197-205.
12. Huang J, Yao JL, Zhang L, Bourne PA, Quinn AM et al. Differential expression of interleukin-8 and its receptors in the neuroendocrine and non-neuroendocrine compartments of prostate cancer. Am J Pathol 2005; 166: 1807-15.
13. Acosta JC, O'Loghlen A, Banito A, Guijarro MV, Augert A et al. Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell 2008; 133: 1006-18.
14. Yao JL, Madeb R, Bourne P, Lei J, Yang X et al. Small cell carcinoma of the prostate: an immunohistochemical study.Am J Surg Pathol 2006; 30: 705-12.
15. Wang W, Epstein JI. Small cell carcinoma of the prostate: A morphologic and immunohistochemical study of 95 cases. Am J Surg Pathol 2008; 32: 65-71.
16. Huang J, Wu C, di Sant'Agnese PA, Yao JL, Cheng L et al. Function and molecular mechanisms of neuroendocrine cells in prostate cancer. Anal Quant Cytol Histol 2007; 29: 128-38.
17. Beltran H, Tagawa ST, Park K, Macdonald T, Milowsky MI et al. Challenges in recognizing treatment-related neuroendocrine prostate cancer. J Clin Oncol 2012; 30: e386-9.
18. Brown JR, Wieczorek TJ, Shaffer K, Salgia R. Smallcell cancers, and an unusual reaction to chemotherapy. Case 1. Extrapulmonary small-cell carcinoma arising in the prostate. J Clin Oncol 2003; 21: 2437-8.
19. Scher HI. Prostate carcinoma: defining therapeutic objectives and improving overall outcomes. Cancer 2003; 97(3 Suppl): 758-71.
20. Chen H, Sun Y, Wu C, Magyar CE, Li X et al. Pathogenesis of prostatic small cell carcinoma involves the inactivation of the P53 pathway. Endocr Relat Cancer 2012; 19: 321-31.
21. Tai S, Sun Y, Squires JM, Zhang H, Oh WKet al. PC3 is a cell line characteristic of prostatic small cell carcinoma. Prostate 2011; 71: 1668-79.
22. Ma J, Ren Z, Ma Y, Xu L, Zhao Y et al. Targeted knockdown of EGR-1 inhibits IL-8 production and IL-8-mediated invasion of prostate cancer cells through suppressing EGR-1/NF-kappa B synergy. J Biol Chem 2009; 284: 34600-6.
23. Reiland J, Furcht LT, McCarthy JB. CXC-chemokines stimulate invasion and chemotaxis in prostate carcinoma cells through the CXCR2 receptor. Prostate 1999; 41: 78-88.
24. van Bokhoven A, Varella-Garcia M, Korch C, Johannes WU, Smith EE et al. Molecular characterization of human prostate carcinoma cell lines. Prostate 2003; 57: 205-25.
25. Slovin SF. Neuroendocrine differentiation in prostate cancer: A sheep in wolf's clothing? Nat Clin Pract Urol 2006; 3: 138-44.
26. Kaplan-Lefko PJ, Chen TM, Ittmann MM, Barrios RJ, Ayala GE et al. Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate 2003; 55: 219-37.
27. Zhou Z, Flesken-Nikitin A, Corney DC, Wang W, Goodrich DW et al. Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer. Cancer Res 2006; 66: 7889-98.
28. Hansel DE, Nakayama M, Luo J, Abukhdeir AM, Park BH et al. Shared TP53 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate. Prostate 2009; 69: 603-9.
29. Beltran H, Rickman DS, Park K, Chae SS, Sboner A et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov 2011; 1: 487-95.
30. Lapuk AV, Wu C, Wyatt AW, McPherson A, McConeghy BJ et al. From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. J Pathol 2012; 227: 286-97.